Myhibbin, mycophenolate mofetil oral suspension
Named-patient access overview. Myhibbin is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Myhibbin
Myhibbin (mycophenolate mofetil oral suspension) is manufactured by Azurity Pharmaceuticals and was approved by the US FDA in 2024 for prophylaxis of organ rejection in adult and pediatric recipients of allogeneic kidney, heart, or liver transplants, used in combination with cyclosporine and corticosteroids. It is a purine synthesis inhibitor that works by selectively and reversibly blocking inosine monophosphate dehydrogenase (IMPDH), suppressing de novo guanosine nucleotide synthesis in T and B lymphocytes. The clinical value of the Azurity formulation is practical: a ready-to-use oral suspension for adult and pediatric patients who cannot reliably swallow capsules or tablets.
Mycophenolate mofetil carries an FDA boxed warning covering embryofetal toxicity (including first-trimester pregnancy loss and congenital malformations), increased risk of lymphoma and other malignancies, and increased risk of serious infections; the prescribing information also requires that prescribers be familiar with transplant immunosuppression. For international patients, Myhibbin may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the patient's treating transplant team handling the documentation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Myhibbin
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Myhibbin for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Myhibbin is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Myhibbin in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Myhibbin
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Myhibbin if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Myhibbin for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Myhibbin through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Myhibbin. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Myhibbin through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Myhibbin to a patient?
Reserve Meds sources Myhibbin from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Myhibbin cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Myhibbin?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.